LINC02582: A Drug Target / Disease Biomarker (G100505817)

Target Name: LINC02582

NCBI ID: G100505817

LINC02582

Other Name(s): long intergenic non-protein coding RNA 2582 | Long intergenic non-protein coding RNA 2582

LINC02582: A Drug Target / Disease Biomarker

LINC02582 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LINC (long non-coding RNA) family, which are characterized by the presence of a conserved core RNA structure and a variable downstream exon array. LINC02582 is also known as lncRNA-RBP1, and it has been identified as a potential drug target or biomarker.

The LINC02582 protein is composed of 219 amino acid residues and has a calculated molecular mass of 30.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and it is highly expressed in the brain. LINC02582 is localized to the cytoplasm and has been shown to be associated with the endoplasmic reticulum (ER) and the nuclear envelope (NE).

One of the most significant features of LINC02582 is its expression pattern. It is highly expressed in the brain and has been shown to be enriched in the prefrontal cortex, a region of the brain that is involved in various cognitive functions. LINC02582 has also been shown to be expressed in other tissues, including the heart and the kidneys.

In addition to its expression pattern, LINC02582 has also been shown to play a role in various cellular processes. For example, it has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival.

Due to its potential role in cellular signaling pathways, LINC02582 has been identified as a potential drug target or biomarker. Studies have shown that LINC02582 can be targeted by small molecules, such as inhibitors of the TGF-β pathway. These small molecules have been shown to have a variety of different effects on cellular behavior, including the inhibition of cell proliferation and the modulation of cellular signaling pathways.

In addition to its potential as a drug target or biomarker, LINC02582 has also been shown to have potential utility as a therapeutic agent. For example, studies have shown that LINC02582 can be overexpressed in cancer cells, which can lead to the development of various cellular alterations, including increased cell proliferation and the formation of cancer stem cells.

Overall, LINC02582 is a protein that has significant potential as a drug target or biomarker. Its expression pattern and involvement in cellular signaling pathways make it an attractive target for small molecule inhibitors. Additionally, its potential utility as a therapeutic agent makes it a promising candidate for future studies.

In conclusion, LINC02582 is a protein that has the potential to be a drug target or biomarker. Its expression pattern and involvement in cellular signaling pathways make it an attractive target for small molecule inhibitors. Additionally, its potential utility as a therapeutic agent makes it a promising candidate for future studies. Further research is needed to fully understand the role of LINC02582 in cellular signaling pathways and its potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 2582

The "LINC02582 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02582 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets